Skip to content

Study · Not a test of the peptide alone · 1994

3 results

Combination treatment with zidovudine, thymosin alpha 1 and interferon-alpha in human immunodeficiency virus infection.

Garaci E, Rocchi G, Perroni L, D'Agostini C, Soscia F, Grelli S, Mastino A, Favalli C

International journal of clinical & laboratory research1 Jan 1994Cited by 29 (Europe PMC)

PMID7910053 (opens in a new tab)DOI10.1007/bf02592405 (opens in a new tab)PepBankPUB-07910053
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 01HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialSafety outcome

    In HIV-infected patients with CD4+ counts of 200 to 500/mm3, combination therapy with thymosin alpha‑1, interferon-alpha and zidovudine was well tolerated after 12 months.

    In plain wordsIn people with HIV, thymosin alpha‑1 plus interferon-alpha and zidovudine was well tolerated over 12 months.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeTolerability after 12 months
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    We thus studied the effects of combination therapy with thymosin alpha 1, interferon-alpha and zidovudine in patients with CD4+ lymphocytes ranging from 200 to 500/mm3 in a randomized non-blinded study and found that the treatment was well tolerated after 12 months of therapy

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 02HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In HIV-infected patients, combination therapy with thymosin alpha‑1, interferon-alpha and zidovudine was associated with a substantial increase in CD4+ T cell number; this was not seen with zidovudine alone or with single agents.

    In plain wordsIn people with HIV, thymosin alpha‑1 plus interferon-alpha and zidovudine was linked to more CD4+ T cells, unlike zidovudine alone or with single agents.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseNumber of CD4+ T cells
    Study

    n: not reported in source

    Comparator
    Zidovudine alone or with single agents
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    was associated with a substantial increase in the number and function of CD4+ T cells.
    1 context sentence
    Summary · context
    A similar effect was not observed in human immunodeficiency virus patients treated with zidovudine alone or associated with single agents.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 03HumanNot a test of Thymosin alpha-1 aloneRandomized controlled trialEfficacy outcome

    In HIV-infected patients, combination therapy with thymosin alpha‑1, interferon-alpha and zidovudine was associated with a substantial increase in CD4+ T cell function; this was not seen with zidovudine alone or with single agents.

    In plain wordsIn people with HIV, thymosin alpha‑1 plus interferon and zidovudine was linked to better CD4+ T cell function, unlike zidovudine alone or single drugs.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseFunction of CD4+ T cells
    Study

    n: not reported in source

    Comparator
    Zidovudine alone or with single agents
    Outcome group
    Immune response · Immune and inflammation

    Source sentences

    Summary
    was associated with a substantial increase in the number and function of CD4+ T cells.
    1 context sentence
    Summary · context
    A similar effect was not observed in human immunodeficiency virus patients treated with zidovudine alone or associated with single agents.

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.